Reviewer's report
Title:Randomized Trial of Tofacitinib in Active Ulcerative Colitis: Analysis of
Efficacy Based on Patient-Reported Outcomes
Version:2Date:28 October 2014
Reviewer: Barrett Levesque
Reviewer's report:
Major Compulsory Revisions
The author must respond to these before a decision on publication can
be reached. For example additional necessary experiments or controls
statistical mistakes errors in interpretation.
Overall, no major compulsory revisions. Overall, a helpful analysis of
IBDQ and IBDPRTI data in the phase 2 tofacitinib trial. Given the
recent emphasis in Patient reported outcome measures, this paper adds
helpful data for those studying the field or using PROs/quality of life
measures in their research.
Minor Essential Revisions
1. Line 307: The results indicate that this PRO could be used as a
complementary endpoint rather than a " a PRO should be.. Complementary².
Other PRO¹s may be more sensitive and specific
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
When completing your declaration please consider the following questions:
-Have you in the past five years received reimbursements fees funding
or salary from an organisation that may in any way gain or lose
financially from the publication of this paper either now or in the future? No.
- Do you hold any stocks or shares in an organisation that may in any
way gain or lose financially from the publication of this paper either
now or in the future?no
- Do you hold or are you currently applying for any patents relating to
the content of the manuscript? Have you received reimbursements fees
funding or salary from an organization that holds or has applied for
patents relating to the content of the manuscript?no
- Do you have any other financial competing interests?
COI: consultant , Takeda; consultant (past) abbvie,
- Do you have any non-financial competing interests in relation to this
paper?
Research in PRO outcome measures
Reviewer's report
Title:Randomized Trial of Tofacitinib in Active Ulcerative Colitis: Analysis of
Efficacy Based on Patient-Reported Outcomes
Version:2Date:28 October 2014
Reviewer: Barrett Levesque
Reviewer's report:
Major Compulsory Revisions
The author must respond to these before a decision on publication can
be reached. For example additional necessary experiments or controls
statistical mistakes errors in interpretation.
Overall, no major compulsory revisions. Overall, a helpful analysis of
IBDQ and IBDPRTI data in the phase 2 tofacitinib trial. Given the
recent emphasis in Patient reported outcome measures, this paper adds
helpful data for those studying the field or using PROs/quality of life
measures in their research.
Minor Essential Revisions
1. Line 307: The results indicate that this PRO could be used as a
complementary endpoint rather than a " a PRO should be.. Complementary².
Other PRO¹s may be more sensitive and specific
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
When completing your declaration please consider the following questions:
-Have you in the past five years received reimbursements fees funding
or salary from an organisation that may in any way gain or lose
financially from the publication of this paper either now or in the future? No.
- Do you hold any stocks or shares in an organisation that may in any
way gain or lose financially from the publication of this paper either
now or in the future?no
- Do you hold or are you currently applying for any patents relating to
the content of the manuscript? Have you received reimbursements fees
funding or salary from an organization that holds or has applied for
patents relating to the content of the manuscript?no
- Do you have any other financial competing interests?
COI: consultant , Takeda; consultant (past) abbvie,
- Do you have any non-financial competing interests in relation to this
paper?
Research in PRO outcome measures
Please review this paper.
user
Reviewer's report
Title:Randomized Trial of Tofacitinib in Active Ulcerative Colitis: Analysis of
Efficacy Based on Patient-Reported Outcomes
Version:2Date:28 October 2014
Reviewer: Barrett Levesque
Reviewer's report:
Major Compulsory Revisions
The author must respond to these before a decision on publication can
be reached. For example additional necessary experiments or controls
statistical mistakes errors in interpretation.
Overall, no major compulsory revisions. Overall, a helpful analysis of
IBDQ and IBDPRTI data in the phase 2 tofacitinib trial. Given the
recent emphasis in Patient reported outcome measures, this paper adds
helpful data for those studying the field or using PROs/quality of life
measures in their research.
Minor Essential Revisions
1. Line 307: The results indicate that this PRO could be used as a
complementary endpoint rather than a " a PRO should be.. Complementary².
Other PRO¹s may be more sensitive and specific
Level of interest: An article whose findings are important to those with closely
related research interests
Quality of written English: Acceptable
Statistical review: No, the manuscript does not need to be seen by a statistician.
Declaration of competing interests:
When completing your declaration please consider the following questions:
-Have you in the past five years received reimbursements fees funding
or salary from an organisation that may in any way gain or lose
financially from the publication of this paper either now or in the future? No.
- Do you hold any stocks or shares in an organisation that may in any
way gain or lose financially from the publication of this paper either
now or in the future?no
- Do you hold or are you currently applying for any patents relating to
the content of the manuscript? Have you received reimbursements fees
funding or salary from an organization that holds or has applied for
patents relating to the content of the manuscript?no
- Do you have any other financial competing interests?
COI: consultant , Takeda; consultant (past) abbvie,
- Do you have any non-financial competing interests in relation to this
paper?
Research in PRO outcome measures
assistant